Affiliation:
1. Department of Endocrinology and Metabolism, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey
2. Department of Nuclear Medicine, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey
3. Department of Internal Medicine, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey
Abstract
Introduction:Thyroid hormones are essential for the normal development, differentiation, metabolic balance and physiological function of all tissues. Mean platelet volume (MPV) indicates mean platelet size and reflects platelet production rate and stimulation. Increased platelet size has been observed in association with known cardiovascular risk factors. The neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) are known markers of the systemic inflammatory response. This study aimed to investigate the effect of thyroid hormone changes by comparing platelet count, MPV values, NLR and PLR in thyroid papillary carcinoma.Methods:Forty-nine females and nine males comprising a total of 58 patients were included in the study. Clinical and laboratory parameters of patients were recorded in the following three phases of the disease: euthyroid phase (before thyroid surgery), overt hypothyroid (OH) phase (before radioactive iodine [RAI] treatment) and subclinical hyperthyroid (SCH) phase (six months after RAI treatment).Results:The mean thyroid-stimulating hormone (TSH) values of the patients in the euthyroid, OH and SCH phases were 1.62±1.17, 76.4±37.5 and 0.09±0.07 μIU/mL, respectively. The mean MPV values of the patients in the euthyroid, OH and SCH phases were 9.45±1.33, 9.81±1.35 and 9.96±1.21 fL, respectively. MPV was significantly higher in the SCH phase than in the euthyroid phase (p=0.013). Platelet count, NLR and PLR were not statistically different between the euthyroid, OH and SCH phases.Conclusion:The results of this study demonstrated that the levels of MPV increased significantly in the SCH phase in patients with papillary thyroid carcinoma (PTC), and increased MPV values contributed to increased risk of cardiovascular complications. These findings suggest that MPV can be a valuable, practical parameter for monitoring the haemostatic condition in thyroid disorders. No significant difference was observed in platelet count, NLR and PLR in all stages of PTC.
Publisher
Bentham Science Publishers Ltd.
Subject
Immunology and Allergy,Endocrinology, Diabetes and Metabolism
Reference53 articles.
1. Bashir H.; Bhat M.H.; Farooq R.; Majid S.; Shoib S.; Hamid R.; Mattoo A.A.; Rashid T.; Bhat A.A.; Wani H.A.; Masood A.; Comparison of hematological parameters in untreated and treated subclinical hypothyroidism and primary hypothyroidism patients. Med J Islam Repub Iran 2012,26(4),172-178
2. Iddah M.A.; Macharia B.N.; Ng’wena A.G.; Keter A.; Ofulla A.V.; Thryroid hormones and hematological indices levels in thyroid disorders patients at moi teaching and referral hospital, Western kenya. ISRN Endocrinol 2013,2013(15)
3. Franchini M.; Montagnana M.; Manzato F.; Vescovi P.P.; Thyroid dysfunction and hemostasis: an issue still unresolved. Semin Thromb Hemost 2009,35(3),288-294
4. Dorgalaleh A.; Mahmoodi M.; Varmaghani B.; Kiani Node F.; Saeeidi Kia O.; Alizadeh Sh.; Tabibian Sh.; Bamedi T.; Momeni M.; Abbasian S.; Kashani Khatib Z.; Effect of thyroid dysfunctions on blood cell count and red blood cell indice. Iran J Ped Hematol Oncol 2013,3(2),73-77
5. Kawa M.P.; Grymuła K.; Paczkowska E.; Baśkiewicz-Masiuk M.; Dąbkowska E.; Koziołek M.; Tarnowski M.; Kłos P.; Dziedziejko V.; Kucia M.; Syrenicz A.; Machalinski B.; Clinical relevance of thyroid dysfunction in human haematopoiesis: biochemical and molecular studies. Eur J Endocrinol 2010,162(2),295-305
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献